| SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders |
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. |
globenewswire.com |
2025-04-25 11:59:00 |
Czytaj oryginał (ang.) |
| SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers |
SciSparc will sell its MitoCareX's shares for $700,000 and exchange its remaining shares for common stock in N2OFF |
globenewswire.com |
2025-03-03 10:25:00 |
Czytaj oryginał (ang.) |
| SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles |
TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the “New Loan”). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. (“JAC”) electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 million (the “Previous Loans”). The Previous Loans were provided in lieu of SciSparc's obligation to provide a $4.25 million closing financing, in accordance with the merger agreement signed between the parties. |
globenewswire.com |
2025-02-27 10:45:00 |
Czytaj oryginał (ang.) |
| SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology |
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has reached an important settlement agreement (the “Settlement”) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company's former directors (the “Defendants”) case number 34426-02-22 (the “Suit”). The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior acquisition of a pain clinic network through a subsidiary of the Company. |
globenewswire.com |
2025-02-18 09:17:00 |
Czytaj oryginał (ang.) |
| Impact Acquisition Enters Into Definitive Agreement to Complete Qualifying Transaction with Jeffs Brands and Fort Products |
February 6, 2025 – TheNewswire - Vancouver, British Columbia – Impact Acquisition Corp. (TSXV: IMPC.P) (“ Impact ”, the “ Company ” or the “ Resulting Issuer ”) is pleased to announce that further to its press release on January 3, 2025, the Company, Jeffs' Brands Ltd, a corporation incorporated under the laws of the State of Israel and listed on the NASDAQ under the trading symbol “JFBR” (“ Jeffs Brands ” or “ JFBR ”), and Jeffs Brands' wholly owned subsidiary, Fort Products Limited (the “ Target ” or “ Fort Products ”) has entered into a definitive agreement dated February 6, 2025 (the “ Definitive Agreement ”), in respect of an arm's length share sale transaction involving the Target Shares (as defined below) (the “ Proposed Transaction ”), which will result in the reverse takeover of the Company by Jeffs Brands. The Proposed Transaction is expected to constitute the Company's “Qualifying Transaction” as such term is defined in policies of the TSX Venture Exchange (the “ Exchange ”). The Proposed Transaction |
thenewswire.com |
2025-02-06 12:20:00 |
Czytaj oryginał (ang.) |
| SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico |
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines. |
globenewswire.com |
2025-02-04 11:00:00 |
Czytaj oryginał (ang.) |
| SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement |
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until July 14, 2025 to regain compliance with Nasdaq's minimum bid price rule. |
globenewswire.com |
2025-01-15 09:34:00 |
Czytaj oryginał (ang.) |
| SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles |
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax's direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors. |
globenewswire.com |
2025-01-13 10:41:00 |
Czytaj oryginał (ang.) |
| SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results |
TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results. |
globenewswire.com |
2025-01-07 09:25:00 |
Czytaj oryginał (ang.) |
| Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? |
On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. |
benzinga.com |
2025-01-06 13:04:50 |
Czytaj oryginał (ang.) |
| SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment |
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a European patent application submitted by Clearmind under the European Patent Office for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. |
globenewswire.com |
2025-01-06 09:50:00 |
Czytaj oryginał (ang.) |
| SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder |
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children with autism spectrum disorder ("ASD"). SCI-210 is a proprietary combination of cannabidiol (“CBD”) and CannAmide™. |
globenewswire.com |
2024-12-31 11:24:00 |
Czytaj oryginał (ang.) |
| S&P 500 Edges Lower, SciSparc Shares Surge |
U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday. |
benzinga.com |
2024-12-26 16:36:17 |
Czytaj oryginał (ang.) |
| SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation |
TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax's direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors. |
globenewswire.com |
2024-12-26 08:46:00 |
Czytaj oryginał (ang.) |
| SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company |
According to the LOI , SciSparc's pharmaceuticals assets are valued at approximately US $11. 6 million |
globenewswire.com |
2024-12-16 09:40:00 |
Czytaj oryginał (ang.) |
| SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment |
FDA confirm s that SciSparc's study may proceed only a month after application submission |
globenewswire.com |
2024-09-30 13:25:00 |
Czytaj oryginał (ang.) |
| SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX |
The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio |
globenewswire.com |
2024-09-26 13:05:00 |
Czytaj oryginał (ang.) |
| SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment |
FDA confirm s that SciSparc's study may proceed following the application submission a month ago |
globenewswire.com |
2024-09-23 12:17:00 |
Czytaj oryginał (ang.) |
| SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment |
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial |
globenewswire.com |
2024-09-18 20:09:00 |
Czytaj oryginał (ang.) |
| SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy |
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. |
globenewswire.com |
2024-09-16 20:06:00 |
Czytaj oryginał (ang.) |
| SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer |
To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto |
globenewswire.com |
2024-09-11 11:40:00 |
Czytaj oryginał (ang.) |
| SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment |
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. |
globenewswire.com |
2024-09-06 11:55:00 |
Czytaj oryginał (ang.) |
| SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination |
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines. |
globenewswire.com |
2024-08-29 20:25:00 |
Czytaj oryginał (ang.) |
| SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million |
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash |
globenewswire.com |
2024-08-28 12:55:00 |
Czytaj oryginał (ang.) |
| SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome |
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel |
globenewswire.com |
2024-08-23 20:09:00 |
Czytaj oryginał (ang.) |
| SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board |
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC |
globenewswire.com |
2024-08-22 12:12:00 |
Czytaj oryginał (ang.) |
| SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment |
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market |
globenewswire.com |
2024-08-19 20:11:00 |
Czytaj oryginał (ang.) |
| Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy |
Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain. |
benzinga.com |
2024-08-19 11:51:56 |
Czytaj oryginał (ang.) |
| SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million |
SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met |
globenewswire.com |
2024-08-16 20:30:00 |
Czytaj oryginał (ang.) |
| Why Is SciSparc (SPRC) Stock Up 94% Today? |
SciSparc (NASDAQ: SPRC ) stock is on the rise Thursday after the clinical-stage pharmaceutical company provided investors with an update concerning its AutoMax Motors merger. The big news here is The Jerusalem District Court in Israel approving AutoMax's petition to convene special class meetings of shareholders to approve the SciSparc merger. |
investorplace.com |
2024-08-15 12:09:44 |
Czytaj oryginał (ang.) |
| SciSparc Updates Regarding the Status of the AutoMax Merger |
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shareholders to approve the Merger with the Company |
globenewswire.com |
2024-08-14 20:53:00 |
Czytaj oryginał (ang.) |